The vascular risk of third generation oral contraceptives;Risque vasculaire des pilules contraceptives de troisieme generation

Journal des Maladies Vasculaires

Volumn 22, Issue 1, 1997, Pages 5-12

  Levesque, H ^a   Borg, J Y ^a   Courtois, H ^a  

^a Dept de Médecine Interne Ctr Hosp Univ Rouen Boisguillaume   (France)

Author keywords

cardiovascular disease; ethinyl estradiol; oral contraceptives; progestational hormones; thromboembolic disease

Indexed keywords

CYPROTERONE ACETATE; DESOGESTREL; DIANE; ESTROGEN; ETHINYLESTRADIOL; ETHINYLESTRADIOL PLUS LYNESTRENOL; ETHINYLESTRADIOL PLUS NORETHISTERONE ACETATE; ETHINYLESTRADIOL PLUS NORGESTREL; GESTAGEN; GESTODENE; LEVONORGESTREL; LYNESTRENOL; LYNESTRENOL PLUS MESTRANOL; MESTRANOL PLUS NORETHISTERONE; NORETHISTERONE; NORETHISTERONE ACETATE; NORGESTIMATE; NORGESTREL; NORGESTRIENONE; NORQUENTIEL; ORAL CONTRACEPTIVE AGENT; OVAMEZZO; PLANOR; UNCLASSIFIED DRUG; UNINDEXED DRUG;

CARDIOVASCULAR DISEASE; FAMILY HISTORY; FEMALE; HUMAN; MUTATION; ORAL DRUG ADMINISTRATION; REVIEW; RISK ASSESSMENT; THROMBOEMBOLISM; VEIN THROMBOSIS;

BLOOD COAGULATION FACTORS; CLINICAL TRIALS; CONTRACEPTIVES, ORAL, HORMONAL; ESTROGENS; FEMALE; HUMANS; PROGESTINS; RISK FACTORS; THROMBOPHLEBITIS; THROMBOSIS;

EID: 0030991755     PISSN: 03980499     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (50)

1. BALL MJ, ASHWELL E, GILLMER MDG. Progestagen-only oral contraceptives : comparison of the metabolic effects of levonorgestrel and norethisterone. Contraception 1991; 44: 223-33.
2. BLOEMENKAMP KWM, ROSENDAAL FR, HELMERSHORST FM, BüLLER HR, VANDENBROUCKE JP. Enhancement by factor V Leiden mutation of risk of deep-vein thrombosis associated with oral contraceptives containing a third-generation progestasen. Lancet 1995 ; 346 : 1593-6.
3. BOEROER LM, MORRIS PC, THURNAU GR, ES.MON CT, COMP PC. Oral contraceptives and gender affect protein S status. Blood 1987; 69: 692-4.
4. BONNAR J, DALY L, CARROL E. Blood coagulation with a combined pill containing gestodene and ethinylestradiol. Int J Fertil 1987 ; J2(suppl.):21-8.
5. BONNAR J. Changes in coagulation and fibrinolysis with low dose oral contraceptives. Adv Contracept 1991 ; 7: 285-91.
6. BRANDT JT, SENHAUSER DA. Effect of oral contraceptives on antithrombin III measurement. Am J Clin Palhol 1979 ; 72 : 134-5.
7. BURINO JE. Low-dose oral contraceptives and stroke. N Enql J Med 1996 ; 335 : 53-4.
8. COHEN J. La contraception stroprogestative : avantages de la diminution des strogènes. Contracept Fertil Sex 1993 ; 2l : 489-94.
9. CRAMER DW. Safety of combined oral contraceptive pills. Lancet 1996; .7: 546.
10. CROOK D, GODSLAND I, WYNN V. Oral contraceptives and coronary heart disease : modulation of glucose tolerance and plasma lipid risk factors by progestins. Am J Obstet Gynecol 1988 ; 158 : 1612-20.
11. CROOK D, GODSLAND I, WORTHINGTON Met al. A comparative study of two-dose oral contraceptives containing gestodene and desogestrel progestins. Am J Obstet Gynecol 1993 ; 169: \183-9.
12. DALY I, BONNAR J. Comparative studies of 30 (ig ethinyl estradiol combined with gestodene and desogestrel on blood coagulation, fibrinolysis and platelets. Am J Obstet Gynecol 1990; 163 : 430-7.
13. DE GRAFF J, SWINKELS D, DEMACKER Pet al. Difference in low density lipoprotein subfraction profile between oral contraceptive users and controls. J Clin Endocrinol Metab 1993 ; 76 : 197-202.
14. DELlGNlEREsB. Safety of combined oral contraceptive pills. Lancet \996\347: 548-9.
15. DENIS C. Contraception estroprogestative : inconvénients de la diminution des estrogènes. Contracept Fertil Sex 1993 ; 27 : 481-8.
16. FAHMY K, KHAIRY M, ALLAM Get al. Effect of depomedroxyprogesterone acaetate on coagulation factors and serum lipids in Egyptian women. Contraception 1991 ; 44 : 431-44.
17. FARMER RDT, PRESTON TD. The risk of thromboembolism associated with low estrogen and contraceptives. J Obstet Gynecol 1995 ; 15: 195-200.
18. GODSLAND IF, CROOK D, SIMPSON R et til. The effects of different formulations of oral contraceptive agents on lipids and carbohydrate metabolism. N Engl J Med 1990 ; 323 : 1375-81.
19. GODSLAND IF, WALTON C, FELTON Cet al. Insulin resistance, secretion and metabolism in users of oral contraceptives. J Clin Eiulocrinol Metab 1992 ; 74 : 64-70.
20. GODSLAND IF, CROOK D. Update on metabolic effects of steroidal contraceptives and their relationship to cardiovascular risk. Am J Obstet Gynccol 1994 ; 170 : 1528-36.
21. HELLOREN M, SVENSSON PJ, DAHLBACK B. Resistance to activated protein C as a basis for venous thromboembolism associated with pregnancy and oral contraceptives. Am J Obstet Gynecol 1995 ;173: 210-3.
22. JICK H, JICK SS, GUREWICH V, MYERS MV, VASILAKIS C. Risk of idiopathic cardiovascular death and non fatal venous thromboembolism in women using oral contraceptives with differing progestagen components. Lancet 1995 ; 346: 1589-93.
23. JUNG-HOFFMANN C, HE1DT F, KüHL H. Effects of two oral contraceptive containing 30 |Jg ethinylestradiol and 75 ng gestodene or 150 |Jg desogestrel upon various hormonal parameters. Contraception 1988 ; 38: 593-603.
24. KAUPPINEN-MAKELIN R, Kuusi T, YLIKORKALA O, TIKKANEN M. Contraceptives containing desogestrel or levonorgestrel have different effects on serum lipoproteins and post-heparin lipase activities. Clin Endocrinol 1992 ; 36 : 203-9.
25. KHAW KT, PERAT W. Blood pressure and contraceptive use. Br Med J 1982 ;285: 403-7.
26. LéVESQUE H, CATLLEUX N, COURTOIS H. Hormonothérapie substitutive de la ménopause, hémostase et risque thrombo-embolique. J Mal Vase 1994 ; 19 : 93-7.
27. LEWIS MA, SPITZER WO, HEINEMANN LAJet al. Third generation oral contraceptive and risk of myocardial infarction : an international case-control study. Br Med J 1996 ; 312 : 88-90.
28. LIDEGAARD O. Oral contraception and risk of a cerebral thromboembolic attack : results of a case control study. Br Med J 1993 ; 306: 956-63.
29. LIDEGAARD O, MILSON I. Oral contraceptives and thrombotic diseases : impact of new epidemiological studies. Contraception 1996;5J: 135-9.
30. MACRAE K, KAY C. Third generation oral contraceptive pills. Br MedJ 1995; 311 : 1111-2.
31. MELIS GB, FRUZETTI F, NICOLETTI I, RICH C, LAMMERS P, ATSMA WJ, FIORETTI P. A comparative study on the effect of a monophasic pill containing desogestrel plus 20 |Jg ethinylestradiol, a triphasic combination containing levonorgestrel and a monophasic combination containing gestodene on coagulary factors. Contraception 1991 ; 43 : 23-31.
32. METROPOLIS K, MILLER G, REEVES Bet al. Factor VII coagulation activity is strongly associated with the plasma concentration of large lipoprotein particles in middle-ace men. Atherosclerosis 1989; 76: 203-8.
33. NOTELOVITZ M, FELDMAN E, GILLEPSY M, GUDAT J. Lipid lipoprotein changes in women taking triphasic contraceptives : a controlled, comparative, 12-month clinical trial. Am J Obstet Gynecol 1989; 160: 1269-80.
34. PABINGER I, KYRLE PA, HEISTINGER M, EICHINGER S, WITTMANN E, LECHNER K. The risk of thromboembolism in asymptomatic patients with protein C and protein S deficiency. A prospective cohort study. Thromb Haemost 1994 ; 71: 441-5.
35. PETITTIDB, SIDNEYS, BERNSTEIN A, WOLF S, QUESENBERRY C, ZIEL HK. Stroke in users of low-dose oral contraceptive. N Engl J Med 1996, 335: 8-15.
36. PLU-BiREAuG, AMIRAL J, GUIZEL, SCARABIN PY. Safety of combined oral contraceptive pills. Lancet 1996 ; 347: 549.
37. POULTER NR, PARLEY TMM, CIIANG CL, MARMOT MG, MEIRIK O. Safety of combined oral contraceptives pills. Lancet 1996 ; 347: 547.
38. SAMSIOE G. Coagulation and anticoagulation effects of contraceptive steroids. Am J Obstet Gynecol 1994 ; J 70 : 1523-7.
39. SPEROFF L, DE CHERNEY A. Evaluation of a new generation of oral contraceptives. Obstet Gynecol 1993 ; SI : 1034-47.
40. SPITZER WO, LEWIS MA, HEINEMANN LAJ, TIIOROGOOD M, M ACRAE KD. On behalf of transnational research group on oral contraceptives and the health of young women. Third generation oral contraceptives and risk of venous thromboembolic disorders : an international case-control study. Dr Mcd J 1996 ; 312 : 83-8.
41. STADEL BV. Oral contraceptives and cardiovascular disease. N Engl J Med 1981 ; 305 : 612-8 (first of two parts).
42. STADEL BV. Oral contraceptives and cardiovascular disease. N Engl J Med 1981 ; 305 : 672-7 (second of two parts).
43. VANDENBROUCKE JP, KOSTER T, BRIET E, REITSMA PH, BERTINA RM, ROSENDAAL FR. Increased risk of venous thrombosis in oral-contraceptive users who are carriers of factor V Leiden mutation. Lancet 1994 ; 344 : 1453-7.
44. WEISS N. Third-generation oral contraceptives : how risky ? Lancet 1995 ;346: 1570.
45. WHO collaborative study of cardiovascular disease and steroid hormone contraception. Ischaemic stroke and combined oral contraceptives : results of an international, multicentre, casecontrol study. Lancet 1996 ; 348 : 498-505.
46. WHO collaborative study of cardiovascular disease and steroid hormone contraception. Haemorrhagic stroke, overall stroke risk, and combined oral contraceptives : results of an international, multicentre, case-control study. Lancet 1996 ; 348: 505-10.
47. WHO collaborative study of cardiovascular disease and steroid hormone contraception. Venous thromboembolic disease and combined oral contraceptives : results of international multicentre case-control study. Lancet 1995 ; 346 : 1572-82.
48. WHO collaborative study of cardiovascular disease and steroid hormone contraception. Effect of different progestagens in low estrogen oral contraceptives on venous thromboembolic disease. Lancet 1995 ; 346 : 1582-88.
49. WINKLER UH, KOSLOWSKI S, SCIIINDLER AE. PAI activity is reduced in users of oral contraceptives-influence of estrogen content. Tliromb Haemost 1989 ; 62 : 394.
50. WlNKLER UH, SCHINDLER AE, ENDRIKAT J, DUSTERBERO B. A comparative study of the effects of the hemostatic system of two monophasic gestodene oral contraceptives containing 20 Hg and 30 (Jg ethinylestradiol. Contraception 1996 ; 53 : 75-84.